Step Pharma is a biotechnology company discovering and developing proprietary small molecule therapeutics for the treatment of auto-immune diseases. Step’s lead program is selective modulators against specific immune cell populations which are the main drivers of auto-immune diseases.

Our Company

Step Pharma Appoints Seasoned Drug Developer Dr. Andrew Parker as Chief Executive Officer

Paris, France, 6 September 2019 – Step Pharma, a biotech company developing novel drugs for autoimmune diseases, today announced the appointment of Andrew Parker, Ph.D., as Chief Executive Officer and member of the Supervisory Board. Dr. Parker joins Step…

Step Pharma Establishes Scientific Advisory Board

Paris, France, 25th February 2018 - Step Pharma, a company focused on the development new oral treatments of a range of autoimmune diseases today announced the establishment of a Scientific Advisory Board to help guide the development of the company's…

Step Pharma Completes €14.5 million Series A Financing with Additional New Investor

Paris, France, 21 November 2017 – Step Pharma today announced the closing of a Series A financing totalling €14.5 million. Pontifax joined existing investors led by Kurma Partners, and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares),…

Contact us for more information